Citadel Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-299,796
| Closed | -$11.8M | – | 15616 |
|
|
2023
Q2 | $11.8M | Buy |
299,796
+277,924
| +1,271% | +$9.8M | ﹤0.01% | 2462 |
|
|
2023
Q1 | $532K | Sell |
21,872
-210,297
| -91% | -$4.6M | ﹤0.01% | 8172 |
|
|
2022
Q4 | $4.97M | Sell |
232,169
-2,326,202
| -91% | -$49.6M | ﹤0.01% | 3873 |
|
|
2022
Q3 | $45.9M | Buy |
2,558,371
+2,388,227
| +1,404% | +$31.3M | 0.01% | 1141 |
|
|
2022
Q2 | $1.64M | Buy |
170,144
+108,471
| +176% | +$1.36M | ﹤0.01% | 5967 |
|
|
2022
Q1 | $1.04M | Buy |
61,673
+30,547
| +98% | +$451K | ﹤0.01% | 7605 |
|
|
2021
Q4 | $520K | Sell |
31,126
-656,654
| -95% | -$10.8M | ﹤0.01% | 9604 |
|
|
2021
Q3 | $11.2M | Buy |
687,780
+291,636
| +74% | +$3.17M | ﹤0.01% | 2890 |
|
|
2021
Q2 | $2.5M | Sell |
396,144
-500,791
| -56% | -$3.23M | ﹤0.01% | 6046 |
|
|
2021
Q1 | $5.54M | Sell |
896,935
-1,739,384
| -66% | -$10.6M | ﹤0.01% | 4032 |
|
|
2020
Q4 | $18.2M | Buy |
2,636,319
+1,434,972
| +119% | +$9.18M | ﹤0.01% | 1905 |
|
|
2020
Q3 | $6.78M | Buy |
1,201,347
+1,147,964
| +2,150% | +$5.47M | ﹤0.01% | 2739 |
|
|
2020
Q2 | $272K | Buy |
+53,383
| New | +$222K | ﹤0.01% | 8065 |
|
|
2020
Q1 | – | Sell |
-27,747
| Closed | -$162K | – | 10380 |
|
|
2019
Q4 | $238K | Buy |
+27,747
| New | +$99.1K | ﹤0.01% | 7936 |
|
|
2018
Q3 | – | Sell |
-17,483
| Closed | -$43.6K | – | 9848 |
|
|
2018
Q2 | $48K | Buy |
+17,483
| New | +$48.2K | ﹤0.01% | 8446 |
|
|
2018
Q1 | – | Sell |
-27,956
| Closed | -$87K | – | 8952 |
|
|
2017
Q4 | $87K | Sell |
27,956
-32,310
| -54% | -$90.8K | ﹤0.01% | 7481 |
|
|
2017
Q3 | $170K | Buy |
60,266
+20,051
| +50% | +$54.1K | ﹤0.01% | 6799 |
|
|
2017
Q2 | $103K | Buy |
40,215
+4,036
| +11% | +$11K | ﹤0.01% | 6894 |
|
|
2017
Q1 | $132K | Sell |
36,179
-45,087
| -55% | -$191K | ﹤0.01% | 6748 |
|
|
2016
Q4 | $393K | Buy |
+81,266
| New | +$2.41M | ﹤0.01% | 5282 |
|
|
2016
Q3 | – | Sell |
-30,836
| Closed | -$1.74M | – | 7928 |
|
|
2016
Q2 | $1.57M | Sell |
30,836
-196,297
| -86% | -$9.8M | ﹤0.01% | 2992 |
|
|
2016
Q1 | $9.6M | Buy |
227,133
+192,941
| +564% | +$9.8M | 0.01% | 1225 |
|
|
2015
Q4 | $2.68M | Buy |
34,192
+25,560
| +296% | +$1.48M | ﹤0.01% | 2443 |
|
|
2015
Q3 | $350K | Sell |
8,632
-12,762
| -60% | -$676K | ﹤0.01% | 5331 |
|
|
2015
Q2 | $1.11M | Buy |
21,394
+1,690
| +9% | +$84.1K | ﹤0.01% | 3817 |
|
|
2015
Q1 | $917K | Sell |
19,704
-12,165
| -38% | -$632K | ﹤0.01% | 4042 |
|
|
2014
Q4 | $1.43M | Buy |
31,869
+21,508
| +208% | +$903K | ﹤0.01% | 3313 |
|
|
2014
Q3 | $403K | Sell |
10,361
-1,056
| -9% | -$41.4K | ﹤0.01% | 4906 |
|
|
2014
Q2 | $483K | Buy |
+11,417
| New | +$419K | ﹤0.01% | 4446 |
|
|
2013
Q4 | – | Sell |
-39,106
| Closed | -$1.16M | – | 7213 |
|
|
2013
Q3 | $1.16M | Buy |
+39,106
| New | +$1.11M | ﹤0.01% | 2943 |
|
Citadel Advisors's ISEE Position: Q3 2023 in Review
Citadel Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 299,796 shares — an estimated $11.8M sold.
Citadel Advisors first reported a position in ISEE in Q3 2013 and held it in 30 quarters. The position peaked at $45.9M in Q3 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Citadel Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 299,796 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $11.8M.
- Citadel Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's IVERIC bio, Inc. Common Stock position peaked at $45.9M in Q3 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.